Actinium Pharmaceuticals ... (ATNM)
1.49
-0.06 (-3.87%)
At close: Mar 24, 2025, 3:59 PM
1.56
4.71%
After-hours: Mar 24, 2025, 07:54 PM EDT
-3.87% (1D)
| Bid | 1.5 |
| Market Cap | 46.48M |
| Revenue (ttm) | 81.32K |
| Net Income (ttm) | -41.08M |
| EPS (ttm) | -1.39 |
| PE Ratio (ttm) | -1.07 |
| Forward PE | -1.85 |
| Analyst | Buy |
| Ask | 1.62 |
| Volume | 535,103 |
| Avg. Volume (20D) | 233,808 |
| Open | 1.59 |
| Previous Close | 1.55 |
| Day's Range | 1.40 - 1.59 |
| 52-Week Range | 1.03 - 10.24 |
| Beta | 0.11 |
About ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 27, 2012
Employees 37
Stock Exchange AMEX
Ticker Symbol ATNM
Website https://www.actiniumpharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ATNM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 235.57% from the latest price.
Stock Forecasts5 days ago
+16.53%
Actinium Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
7 months ago
+15.73%
Actinium Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results.
